SCHEMBL1293

SCHEMBL1293

CC(=O)CCc1ccccc1Cl

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IAPP P10997 1/20 0.55
ALDH1A1 P00352 2/20 0.54
LMNA P02545 1/20 0.54
TAAR1 Q96RJ0 3/20 0.50
PLAAT3 P53816 2/20 0.50
PLAAT5 Q96KN8 2/20 0.50
PLAAT2 Q9NWW9 2/20 0.50
PLAAT4 Q9UL19 2/20 0.50
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
SLC6A2 P23975 1/20 0.47
SLC6A4 P31645 1/20 0.47
SLC6A3 Q01959 1/20 0.47
AOC3 Q16853 1/20 0.47
CASP3 P42574 1/20 0.47
CASP7 P55210 1/20 0.47
MAOA P21397 1/20 0.46
MAOB P27338 1/20 0.46
HTT P42858 1/20 0.46
HTR3E A5X5Y0 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31612133 1.00 IAPP (0.55) IAPPALDH1A1LMNATAAR1PLAAT3
SCHEMBL14492582 0.96 ALDH1A1 (0.51) IAPPALDH1A1LMNATAAR1PLAAT3
Magnesium Chloride Anhydrous SCHEMBL28689545 0.94 ALDH1A1 (0.50) IAPPALDH1A1LMNATAAR1PLAAT3
SCHEMBL13235696 0.85 IAPP (0.56) IAPPALDH1A1LMNATAAR1SLC6A2
SCHEMBL7331092 0.83 TAAR1 (0.54) TAAR1PLAAT3PLAAT5PLAAT2PLAAT4
SCHEMBL6100122 0.83 TAAR1 (0.54) ALDH1A1TAAR1PLAAT3PLAAT5PLAAT2
Ethane SCHEMBL10497410 0.82 FFAR1 (0.56) TAAR1PLAAT3PLAAT5PLAAT2PLAAT4
SCHEMBL8277219 0.82 MAOA (0.54) ALDH1A1LMNANPC1RAB9AMAOA
SCHEMBL30323279 0.82 IAPP (0.53) IAPPALDH1A1LMNAPLAAT3PLAAT5
SCHEMBL455219 0.82 FFAR1 (0.59) TAAR1PLAAT3PLAAT5PLAAT2PLAAT4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240228495-A1 Tricyclic Inhibitors of Influenza Virus Endonuclease STANFORD RES INST INT (US) 2024-07-11 US disclosed
US-20230348369-A1 NAMPT MODULATORS CYTOKINETICS, INC. 2023-11-02 US disclosed
US-20230016922-A1 VISIBLE-LIGHT MEDIATED ORGANOPHOTOREDOX CATALYTIC DEUTERATION OF AROMATIC AND ALIPHATIC ALDEHYDES NATIONAL INSTITUTES OF HEALTH 2023-01-19 US disclosed
US-20220009876-A1 METHOD FOR SYNTHESIZING D3 DOPAMINE RECEPTOR AGONISTS POLYCORE THERAPEUTICS 2022-01-13 US disclosed
WO-2021226276-A2 NAMPT MODULATORS CYTOKINETICS, INC. (US) 2021-11-11 WO disclosed
CN-108721283-A Application of the thiazole in treating non-lymphocytic leukemia 华东理工大学 2018-11-02 CN disclosed
US-9624182-B2 Compounds as lysophosphatidic acid receptor antagonists AMIRA PHARMACEUTICALS, INC. (US) 2017-04-18 US disclosed
EP-2483252-B1 COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS AMIRA PHARMACEUTICALS INC (US) 2017-03-08 EP disclosed
US-20150329502-A1 COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS AMIRA PHARMACEUTICALS, INC. (US) 2015-11-19 US disclosed
US-9090573-B2 Compounds as lysophosphatidic acid receptor antagonists AMIRA PHARMACEUTICALS, INC. (US) 2015-07-28 US disclosed
US-6548546-B2 Administering a 2-hydroxy-4-oxo- or 4,6-dioxo-6-pheny-l or naphthyl- hex-2-enoic acid; viricides; AIDS/ARC BRISTOL-MYERS SQUIBB COMPANY 2003-04-15 US disclosed
EP-1275635-A1 Calcium receptor-active compounds NPS PHARMACEUTICALS, INC. (US) 2003-01-15 EP disclosed
US-20020123527-A1 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2002-09-05 US disclosed
EP-1203761-A2 Calcium receptor-active compounds NPS PHARMACEUTICALS, INC. (US) 2002-05-08 EP disclosed
WO-2001098248-A2 HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2001-12-27 WO disclosed
US-6211244-B1 AROMATIC AMINES FOR COMPLEXING CALCIUM NPS PHARMACEUTICALS, INC. 2001-04-03 US disclosed
WO-1996012697-A9 CALCIUM RECEPTOR-ACTIVE COMPOUNDS NPS PHARMA INC (US) 2000-08-24 WO disclosed
EP-0787122-A2 CALCIUM RECEPTOR-ACTIVE COMPOUNDS NPS PHARMACEUTICALS, INC. (US) 1997-08-06 EP disclosed
WO-1996012697-A2 CALCIUM RECEPTOR-ACTIVE COMPOUNDS NPS PHARMACEUTICALS, INC. (US) 1996-05-02 WO disclosed
US-5288726-A Tetrahydrothienopyridine derivatives, furo and pyrrolo analogs thereof and their preparation and uses for inhibiting blood platelet aggregation UBE INDUSTRIES LIMITED (JP) 1994-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220009876-A1 METHOD FOR SYNTHESIZING D3 DOPAMINE RECEPTOR AGONISTS DRD3, DRD2, HTR3A IAPP 1085/4885ALDH1A1 865/4885LMNA 4798/4885
US-20230348369-A1 NAMPT MODULATORS NAMPT, NNT, NAPRT IAPP 2144/4885ALDH1A1 982/4885LMNA 1650/4885
US-20240228495-A1 Tricyclic Inhibitors of Influenza Virus Endonuclease RNASEH1, RNASEL, DNASE1 IAPP 4369/4885ALDH1A1 802/4885LMNA 1328/4885
US-20150329502-A1 COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS LPAR1, LPAR2, LPAR4 IAPP 1478/4885ALDH1A1 3726/4885LMNA 787/4885
US-20020123527-A1 HIV integrase inhibitors POLM, NPC1, AP1M1 IAPP 4799/4885ALDH1A1 1245/4885LMNA 978/4885
US-20230016922-A1 VISIBLE-LIGHT MEDIATED ORGANOPHOTOREDOX CATALYTIC DEUTERATION OF AROMATIC AND ALIPHATIC ALDEHYDES AOX1, TDO2, TALDO1 IAPP 4810/4885ALDH1A1 34/4885LMNA 3175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.